Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ralph Alderson
Development of PF-06671008, a Highly Potent Anti-P-Cadherin/Anti-Cd3 Bispecific DART Molecule With Extended Half-Life for the Treatment of Cancer
Antibodies
Drug Discovery
Allergy
Immunology
Related publications
Initial Experience With the Bispecific Anti-Cea Anti-Cd3 Antibody and Its Expected Impact on Future Treatment for Patients With Colorectal Cancer
ESMO Open
Cancer Research
Oncology
A Novel Asymmetrical Anti-Her2/Cd3 Bispecific Antibody Exhibits Potent Cytotoxicity for HER2-positive Tumor Cells
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
An Anti–glypican 3/Cd3 Bispecific T Cell–redirecting Antibody for Treatment of Solid Tumors
Science Translational Medicine
Medicine
Development and Clinical Application of Anti-Her2 Monoclonal and Bispecific Antibodies for Cancer Treatment
Experimental Hematology and Oncology
Cancer Research
Oncology
Hematology
Phase I Study of Anti-Cd3 X Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
Prostate Cancer
Cancer Research
Oncology
Urology
A Novel GUCY2C-CD3 T Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Clinical Cancer Research
Cancer Research
Oncology
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
AAPS Journal
Pharmaceutical Science
New Composites of Betulin Esters With Arabinogalactan as Highly Potent Anti-Cancer Agents
Natural Product Research
Biochemistry
Analytical Chemistry
Plant Science
Organic Chemistry
Discovery of a Small Molecule Having Both Potent Anti-Fibrotic and Anti-Inflammatory Capabilities
